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Abstract 
 
Background Non-vitamin K oral anticoagulants (NOACs) have become an appealing alternative 
treatment for the prevention of stroke in non-valvular atrial fibrillation and in treatment of venous 
thromboembolism. The major limitation to the use of these drugs is the lack of reversal agents. The 
purpose of this review is to investigate the development and efficacy of novel agents for reversal of 
NOACs. Methods Two separate literature searches were conducted in the PubMed database using 
the terms “prothrombin complex concentrate” and “idarucizumab”, respectively. Only in vivo clinical 
trials involving human subjects published within the last five years were included for possible 
analysis. Studies with disease-specific populations (i.e. non-valvular atrial fibrillation, etc.) were 
excluded. Three studies were chosen based on these inclusion and exclusion criteria. Results A 
phase I trial investigating Cofact, a non-activated, four factor prothrombin complex concentrate 
(PCC), demonstrated that Cofact normalized the prothrombin time (PT) and endogenous thrombin 
potential (ETP) in all participants anticoagulated with rivaroxaban but had no effect on the 
prolongation of the activated partial thromboplastin time (aPTT) and ecarin clotting time (ECT) in 
participants anticoagulated with dabigatran etexilate. In another phase I trial clinical trial, 
idarucizumab, at doses of 4 and 5 + 2.5 g, effectively reversed anticoagulation with dabigatran 
etexilate immediately and at 24 hours, as assessed by the dilute thrombin time (dTT), ECT, thrombin 
time (TT), and aPTT. An ongoing phase III clinical trial with 5 g idarucizumab also demonstrated 
effective reversal of dabigatran etexilate in roughly 86 percent of patients at 24 hours. Conclusion 
Only idarucizumab has been approved by the FDA for clinical use. Therefore, dabigatran etexilate is 
preferable to the factor Xa inhibitors for oral anticoagulation in adult patients, based on the current 
availability of an approved, effective reversal agent.  
 
Introduction 
 
 Until 2009, warfarin was the mainstay of treatment for patients with non-valvular atrial 
fibrillation (NAF), thrombophilia, or those at risk for venous thromboembolism (VTE). However, 
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due to warfarin’s variable pharmacokinetic profile, researchers and clinicians were eager to find 
an effective alternative to the drug. Clinicians also recognized that patients would more readily 
comply with a treatment regimen that required fewer dietary restrictions and less frequent 
coagulation monitoring. Dabigatran etexilate (dabigatran), a direct thrombin inhibitor, was 
approved by the FDA in 2009 for treatment of NAF and in 2010 for treatment of VTE. The direct 
factor Xa inhibitors (rivaroxaban, edoxaban, and apixaban) were subsequently approved by the 
FDA for treatment of NAF and VTE. These drugs collectively comprise the “NOAC” 
anticoagulants, that is, non-vitamin K oral anticoagulants. Since their approval, the NOACs have 
been an appealing alternative to treatment with warfarin, as these drugs do not require routine 
lab monitoring, dietary restrictions, and have a more reliable pharmacokinetic profile. However, 
the main clinical concern with the NOACs is that no reversal agents for these drugs exist. 
 In 2013, the FDA approved non-activated 4-factor prothrombin complex concentrate 
(PCC) for the rapid reversal of vitamin K antagonists (VKAs) such as warfarin. Recent studies 
have also examined the effectiveness of PCC in reversing direct factor Xa and direct thrombin 
inhibitors. PCC is a coagulation factor replacement product containing factors II, VII, IX and X, 
heparin, protein C and S, antithrombin III and human albumin. It is a blood product derived from 
human plasma and administered intravenously for emergent reversal of oral anticoagulants1.  
 Recent studies have also investigated idarucizumab, a humanized mouse monoclonal 
antibody fragment, as a potential agent for dabigatran etexilate reversal. Idarucizumab is 
administered intravenously for patients requiring emergent reversal of anticoagulation therapy 
with dabigatran2. During in vitro and in vivo studies, idarucizumab binds dabigatran with an 
affinity that is 300 times greater than the affinity of dabigatran for thrombin, to such an extent 
that idarucizumab will bind dabigatran that is already in complex with thrombin. The dabigatran-
idarucizumab complex is then excreted by the kidneys2,3. 
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 With the increasing clinical use of NOACs, there is a growing need for an effective 
antidote. As such, we conducted this review to examine ongoing research of reversal agents for 
NOACs, a riveting topic for both patients and clinicians.   
 
Clinical Scenario  
 
 K.M. is a 57 year old black male who began taking dabigatran (Pradaxa) two years ago 
when he was diagnosed with non-valvular atrial fibrillation. The only other medication he takes 
is ibuprofen for chronic knee pain. Today, he presents to the emergency department with a two 
week history of epigastric abdominal pain, nausea, dizziness on standing, and dark stool. K.M. 
also has a history of gastroesophageal reflux disease and says he has been treated for a 
“stomach ulcer” in the past. Based on his history, physical examination, and chest X-ray 
showing free air under the right hemidiaphragm, the ER physician assistant determines that 
K.M. needs emergent surgery for a perforated gastric ulcer. Are there any existing agents 
clinically available for anticoagulation reversal?  
 
Clinical Question 
 
 Among male and female patients taking NOACs as oral anticoagulant therapy, is 
reversal of direct factor Xa inhibitors with prothrombin complex concentrate (PCC) more 
effective than reversal of direct thrombin inhibitors with idarucizumab for cases of major 
bleeding or requiring emergent or invasive surgery (figure 1)? 
 
 
 
 
Population Men and women taking oral anticoagulants 
Intervention prothrombin complex concentrate for reversal of direct factor Xa inhibitors (i.e. rivaroxaban) 
Comparison idarucizumab for reversal of direct thrombin inhibitors (i.e. dabigatran)  
Outcome effective reversal of major bleeding and for cases requiring emergent invasive surgery 
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 Figure 1: Study PICO used to formulate the clinical question. 
 
Methods 
 
 Two separate PubMed searches were conducted using the search terms “prothrombin 
complex concentrate” and “idarucizumab”, respectively. Inclusion criteria for both searches 
included publication within the last five years. The randomized control trial (RCT) filter was 
selected only during the PCC search because doing so in both searches would have excluded a 
pivotal prospective cohort study of idarucizumab that could not ethically be conducted as a 
RCT. Therefore, the “clinical trial” filter was selected during the idarucizumab search instead of 
“RCT”.  
Articles were excluded if the studies did not involve 
dabigatran or rivaroxaban, examined reversal agents 
other than PCC and idarucizumab, or included study 
populations that were too disease-specific (i.e. non-
valvular atrial fibrillation, etc.). Further exclusion 
criteria included animal studies and ex vivo studies 
(figure 2). 
Results - Idarucizumab Phase I Trial 
Glund et al. examined a population of 47 white males 
deemed healthy based on their body mass index and      
normal creatinine clearance. The study design was a 
randomized, placebo-controlled phase I trial utilizing paid volunteers at a single study site in 
Belgium. Phase I trials are the first testing phase after animal testing in the FDA drug review 
process4. All participants were given at least one dose of 220 mg dabigatran etexilate prior to 
treatment with idarucizumab or placebo. One goal of the study was to determine a dose of 
idarucizumab to effectively reverse dabigatran, so participants were divided into four treatment 
Figure 2: PRIMSA diagram. 
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groups, receiving 1, 2, 4, and 5 + 2.5 g of idarucizumab, respectively (table 1). Idarucizumab or 
placebo were given as a five minute infusion, except the 5 + 2.5 g dose, which was given as two 
separate infusions one hour apart. Blood samples were drawn from all participants at baseline, 
immediately following administration of idarucizumab or placebo, and at 2, 4, 6, 8, 10, 12, 14, 
18, and 24 hours. Samples were assessed for reversal with the dilute thrombin time (dTT), 
ecarin clotting time (ECT), activated partial thromboplastin time (aPTT), endogenous thrombin 
potential (ETP), and fibrinopeptide A concentrations in shed blood. The study authors created a 
study-specific upper limit of normal (ULN) for each of the coagulation assays, using data 
collected from the 47 study participants on two separate days before treatment with 
idarucizumab as well as data from 16 volunteers in a different arm of the study. Total and 
unbound dabigatran concentrations were assessed to correlate with coagulation assays. 
Participants were followed up at one and three months after idarucizumab administration to 
determine if any adverse events had occurred and to test for the formation of anti-drug 
antibodies to idarucizumab.  
Dabigatran prolonged all coagulation assays in all participants, and the 2, 4, and 5 + 2.5 
g infusions of idarucizumab completely and immediately reversed the prolongation of all assays. 
The 1 g dose completely and immediately reversed the effects of dabigatran, however at two 
hours after administration of idarucizumab, clotting times for all coagulation assays (dTT, ECT, 
aPTT, and TT) except the ACT had increased to greater than the ULN. Only the 4 and 5 + 2.5 g 
doses of idarucizumab were effective in sustaining reversal of coagulation assays at 72 hours, 
 Idarucizumab Placebo Total 
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Table 1: Number and distribution of patients randomized to the four dosing arms of the Glund et 
al. study examining the ability of idarucizumab to reverse anticoagulation with dabigatran 
etexilate.  
 
indicating that the reversal of dabigatran’s anticoagulant effects with idarucizumab is dose-
dependent. No procoagulant effects or clinically relevant adverse events occurred among the 
participants at any time during the study or at follow-up. The main adverse events after 
idarucizumab administration included hot flashes, infusion site erythema, and hematoma. 
Because no significant adverse events occurred with idarucizumab administration, the drug was 
deemed an effective and well-tolerated reversal agent for dabigatran, and further study in the 
REVERSE-AD trial was able to proceed2.   
 
Results - Idarucizumab Phase III Cohort Study 
 
 Pollack et al. are conducting an ongoing phase III clinical trial, and the article in review is 
an interim analysis of 90 patients. Phase III clinical trials are the final testing phase in the FDA 
drug review process4. The study design is a prospective cohort study, as the study authors 
determined it would be unethical to withhold a potential treatment from patients presenting with 
major bleeding or in need of urgent surgery.  
 90 dabigatran-prescribed patients presented at 184 different international sites between 
June 2014 and February 2015 (see Table 2 for patient characteristics). Inclusion criteria were 
either (a) patients with overt, uncontrollable, or life-threatening bleeding or (b) patients requiring 
urgent surgery or other invasive procedure that could not be delayed for 8 hours. These patients 
1 g 9 3 12 
2 g 9 3 12 
4 g 8 3 11 
5 + 2.5 g 9 3 12 
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were divided into groups A (n = 51) or B (n = 39), respectively. Clinical characteristics of 
patients are presented in table 2.  
Table 2: Clinical characteristics of patients in the REVERSE-AD trial 
 Group A 
n = 51 
Group B 
n = 39 
Hemodynamically unstable with ongoing blood loss 16  
Intracranial hemorrhage 18  
GI bleeding 20  
Bleeding from trauma 9  
Other causes 11  
Patients taking 110 mg BID 34 24 
Patients taking 150 mg BID 14 15 
Elevated dTT at baseline 40 28 
Elevated ECT at baseline 47 34 
Median age (years) 77 76 
Median weight (kg) 70.5 73 
Median CrCl (mL/min) 54 60 
Median time since last dose dabigatran (hours) 15.2 16.6 
Bone fractures  8 
Acute Cholecystitis  5 
Acute renal insufficiency, catheter placement  4 
Acute appendicitis  3 
Joint wound infection  3 
Abscess (suprapubic, scrotal)  2 
Aortic dissection  1 
Acute deterioration of aortic valve  1 
Pericardial tamponade  1 
Small bowel obstruction  1 
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Table 2: Clinical characteristics of patients in the REVERSE-AD trial 
 Group A 
n = 51 
Group B 
n = 39 
Pneumothorax  1 
Perforation of viscera  1 
Incarcerated umbilical hernia  1 
Peritonitis  1 
Lumbar puncture  1 
Leg gangrene  1 
Unstable angina  1 
Hydronephrosis/ureteral obstruction  1 
 
 
 All patients were treated with 5 g of idarucizumab, which was administered as two 50 mL 
bolus IV infusions containing 2.5 g, separated by no more than 15 minutes. Blood samples were 
collected at baseline, after the first 2.5 g infusion of idarucizumab, between 10-30 minutes after 
the second 2.5 g infusion, and at 1, 2, 4, 12, and 24 hours. These blood samples were 
assessed by the dTT, ECT, and total and unbound plasma concentrations of dabigatran at a 
central laboratory to determine the maximum percentage reversal of dabigatran. The aPTT and 
TT were evaluated by local laboratories at 1, 2, 12, and 24 hours but also at a central 
laboratory. Any thrombotic events or deaths that occurred up to 90 days after idarucizumab was 
administered were evaluated by an adjudication committee. 88 patients were followed until 
death or for at least one month. 
 Only 68 of 90 patients were used to assess the maximum percentage reversal with 
idarucizumab by dTT, as 22 patients had a normal dTT at baseline. Only 81 of 90 patients were 
included in evaluation of maximum percentage reversal with ECT, as 9 patients had a normal 
ECT at baseline. These 9 patients also had a normal dTT. Patients with normal dTT and ECT 
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results at baseline had a greater creatinine clearance and longer time since the last ingested 
dose of dabigatran than those patients with elevated dTT and ECT results at baseline. 
Interestingly, within group A, intracranial hemorrhage occurred more frequently among patients 
with normal baseline coagulation assays than those with elevated baseline values. Other 
differences are described in table 3. 
 After administration of idarucizumab, the dTT was normalized in 98% of patients in 
group A and 93% of patients in group B who could be evaluated after the first infusion. The ECT 
was normalized in 89% of patients in group A and 88% of group B who could be evaluated after 
the first infusion. At 24 hours, reversal based on dTT results was sustained below the                             
study-specific ULN in 72% of group A patients and 54% of group B patients who could be 
evaluated.  
 Patients with elevated coagulation 
assays at baseline 
Patients with normal coagulation 
assays at baseline 
Number of participants (dTT) 68 22 
Number of participants (ECT) 81 9 
Median creatinine clearance 67 mL/minute 48 mL/minute 
Median time since last dose of 
dabigatran etexilate 
12.8 hours 30.3 hours 
Percentage with intracranial 
bleeding (group A)  
28% (n=40) 64% (n=11) 
Number of thrombotic events 3 2 
Number of deaths 17 1 
 Table 3: Characteristics of patients with normal and elevated coagulation assay results at   
  baseline in the phase III Pollack et al. study with idarucizumab. Patients with normal coagulation  
 assay results at baseline were not included in the efficacy analysis with dTT and ECT but were  
 still included in the study.  
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 Concentrations of total and unbound dabigatran were assessed in all patients at 
baseline, after administration of the first vial of idarucizumab, after administration of the second 
vial of idarucizumab, and at 1, 2, 4, 12, and 24 hours. Before idarucizumab administration, 
median baseline plasma concentrations of unbound dabigatran were 84 ng/mL, and after the 
first 2.5 g were given, unbound dabigatran concentrations decreased to less than 20 ng/mL in 
89 of 90 patients. 
 18 patients died during the clinical trial. The adjudication committee, independent from 
the Boehringer Ingelheim study group, determined that deaths occurring within 96 hours of 
receiving idarucizumab were attributable to the precipitating event, while deaths after 96 hours 
were due to existing comorbidities. Five patients experienced thrombotic events, including deep 
vein thrombosis, pulmonary embolism, myocardial infarction, and ischemic stroke, however 
none of these five patients had been restarted on anticoagulant therapy when the event 
occurred. Most patients were restarted on various anticoagulant therapies (n = 72). 21 patients 
experienced serious adverse events including death and thrombotic events, which are listed in 
table 43. 
Death 18 
Thrombotic events 5 
Gastrointestinal hemorrhage 2 
Postoperative wound infection 1 
Delirium 1 
Right ventricular failure 1 
Pulmonary edema 1 
Table 4: Serious adverse events that occurred among study participants in the phase III trial with 
idarucizumab. Note: some patients experienced more than 1 adverse event. 
 
Results - PCC Phase I Trial 
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 Eerenberg et al. conducted the first randomized, double-blind, placebo-controlled phase 
I clinical trial to evaluate the efficacy and safety of Cofact, a prothrombin complex concentrate 
(PCC), in reversing the anticoagulant effects of rivaroxaban and dabigatran. This 2011 study 
included 12 healthy male participants, ages 20-28, with BMIs of 23 + 3 kg/m2 and normal liver 
and kidney function. Six of the participants received 20 mg rivaroxaban twice daily and six 
received 150 mg dabigatran twice daily, each for 2.5 days. Baseline coagulation assay values 
were determined prior to administration of PCC or placebo. Prothrombin time (PT) and 
endogenous thrombin potential (ETP) were the coagulation assays chosen to evaluate the 
Cofact’s reversal of rivaroxaban. Ecarin clotting time (ECT), aPTT, thrombin time (TT), and ETP 
lag time were used to evaluate Cofact’s reversal of dabigatran. 50 IU/kg of Cofact was chosen 
because this dose was seen to be the most effective in prior animal studies. Blood samples 
were collected at 15 minutes, 30 minutes, 1, 2, 3, 6, and 24 hours after PCC administration. 
After a “washout period” of 11 days, the same procedure was repeated, with each group of 6 
participants receiving the other anticoagulant. All participants were observed at the clinical trial 
unit of the cardiac care unit at the Academic Medical Center in Amsterdam. An automated 
coagulation analyzer was used (Behring Coagulation System XP) for the PT, aPTT and TT. ETP 
was calculated by Thrombinoscope software. 
 Reversal of anticoagulation with rivaroxaban was demonstrated by normalization of the 
PT and ETP after administration of Cofact and shown to be statistically significant. Rivaroxaban 
prolonged the PT from a baseline of 12.3 + 0.7 seconds to 15.8 + 1.2 seconds (P < 0.001). PT 
normalized to 12.8 + 1.0 seconds after the IV infusion of Cofact but remained at 16 seconds 
after IV infusion of the saline placebo (figure 3). The changes in PT were statistically significant 
(P < 0.001) and illustrated the effectiveness of Cofact on reversing rivaroxaban versus the 
placebo infusion of saline. ETP was 92 + 22% at baseline and decreased after administration of 
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rivaroxaban to 51 + 22% (P = 0.002). After administration of Cofact, the ETP normalized to 114 
+ 26% (P < 0.001) but did not increase with placebo. 
 
 
 
Figure 3: Changes in prothrombin time (PT) over time with Cofact versus  
saline administration.  
 
 
 Pre-treatment with dabigatran prolonged the ECT, TT and aPTT, and the administration 
of Cofact did not normalize these coagulation assays. Dabigatran prolonged the aPTT from a 
baseline of 33.6 + 3.3 seconds to 59.4 + 15.8 seconds, and Cofact did not normalize the aPTT 
(70.3 + 15.1 seconds). TT was > 120 seconds after dabigatran pre-treatment and remained 
prolonged after both Cofact and saline infusion. At baseline, the ECT was 33 + 1 seconds and 
significantly increased after dabigatran pre-treatment to 69 + 26 seconds. Again, neither Cofact 
nor saline reversed ECT prolongation, which actually continued to increase to 86 + 20 seconds. 
Cofact successfully reversed the anticoagulant effects of rivaroxaban but was not effective in 
neutralizing anticoagulation with dabigatran. 
 No major bleeding or adverse events occurred during the study. Two patients receiving 
rivaroxaban developed a minor hematoma at the infusion site. Among dabigatran-treated 
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patients, two developed a minor infusion-site hematoma, one experienced gingival bleeding, 
and one experienced a minute-long episode of epistaxis1.  
 
 Discussion 
 
 The development of a reversal agent for NOACs is an exciting breakthrough for 
clinicians and patients, and it is important that research into the efficacy of these drugs be 
carried out meticulously and published in a manner that clearly and honestly explains the 
research findings. In reviewing the studies that have been previously discussed, there were 
several factors within each that threaten the accuracy, reliability, and validity of the studies, in 
spite of their favorable results. 
 Glund et al. demonstrated that idarucizumab doses greater than 2 g completely and 
sustainedly reverse of anticoagulation with dabigatran in healthy individuals and with minimal 
adverse events. These promising results allowed further study in a phase III clinical trial 
(REVERSE-AD) to proceed, yet there are key limitations to this phase I idarucizumab study. 
Most importantly, there is a major discrepancy and apparent deviation from study protocol 
concerning the amount of dabigatran each participant received prior to treatment with 
idarucizumab. The authors first state that all participants were given dabigatran for three days at 
a dosage of 220 mg twice daily. However, in the results section, the authors state that all study 
participants received at least one dose of dabigatran at 220 mg, which would produce very 
different levels of dabigatran in the body than a cumulative three days of twice daily dabigatran 
dosing. Dabigatran has a wide volume of distribution in the human body and equilibrates 
between the blood and tissues. As this study was performed on healthy volunteers who 
presumably had never taken dabigatran, they would not have stores of dabigatran in their 
tissues. However, after three days of twice daily dosing with 220 mg dabigatran, the volunteers 
could potentially accumulate dabigatran stores that would mimic that of patients who have been 
taking dabigatran long-term. All of the participants did not receive the same number of doses of 
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dabigatran, which could have contributed to the ease of reversal. With only one dose of 
dabigatran and reversal with idarucizumab as early as 2 hours later, dabigatran would not have 
built up a significant store in the tissues and would easily be neutralized by idarucizumab. The 
difference in the dabigatran tissue concentrations of healthy versus “unhealthy” study 
participants could also have contributed to the difference in the ability of idarucizumab to 
sustainedly reverse dabigatran-induced anticoagulation in the phase I and III idarucizumab 
trials. 
  There are several limitations in common among the studies. Statistical significance 
testing was not performed in either the phase I or phase III idarucizumab trials, however, it was 
performed in the PCC trial. In place of statistical significance testing, the phase III authors used 
descriptive statistics (quartiles, etc.), and the phase I authors used descriptive statistics with 
linear regression modeling. This lack of statistical significance testing introduces doubt 
concerning the validity of the results. 
 Reliability and validity can be further questioned based on the lack of statistical power 
calculations. Statistical power is limited among the three studies, as each had sample sizes of 
less than 100 participants. The PCC trial with 12 participants is especially limited in its statistical 
power, with a resultant increase in the probability of type I error. 
 Another limitation among the studies lies in the presentation of data. Unlike the PCC 
article, which has straightforward figures and graphs that include mean data points ± standard 
deviation values, the graphs in the phase I and III idarucizumab articles were difficult to interpret 
and did not clearly illustrate the results of the study. In figure 2 of the phase I article (figure 4), 
the size and range of the graphs’ y-axes resulted in overlap of data points and made the 
determination of precise data points difficult. In the phase III idarucizumab trial, the box and 
whisker plots would have been more effective if the scales of the y-axes had been increased 
and the range decreased. Tables with exact values were provided in the supplementary 
appendix, but the visual representation of the data in the primary published article were difficult  
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Figure 4: Image of figure 2 from the phase I idarucizumab trial article “Safety, tolerability, and 
efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male 
volunteers: A randomised, placebo-controlled, double-blind phase 1 trial”. 
to interpret independently. Another concern with the box and whisker plots is that many percent 
calculations were made throughout the article, presumably from data presented in these plots. 
This statistical approach may allow misrepresentation of the study results, as the box and 
whisker plots allow the authors to make statements about percent efficacy without revealing the 
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number of patients used to make these calculations. This statistical approach may allow for 
misrepresentation of the results of this study. 
 In addition to the unclear visual representation of data in the phase I and phase III 
idarucizumab trials, there are notable discrepancies in the textual presentation of data collection 
and results, specifically in the phase III idarucizumab study. The execution of this trial and the 
presentation of its results continually raises questions about the validity of the study findings and 
conclusion. The study authors make conflicting statements about the number of patients 
included in the efficacy analysis with the dilute thrombin time (dTT) and ecarin clotting time 
(ECT). At the beginning of their results, the authors state that 22 patients were excluded from 
efficacy analysis with dTT due to normal dTT results at baseline, and likewise that 9 patients 
were excluded from efficacy analysis with ECT due to normal baseline results. However, in a 
later figure caption, the authors state that all 90 patients were included in efficacy analyses 
using the dTT and ECT3. Blood samples were missing from four patients at four hours, seven 
patients at 12 hours, and 12 patients at 24 hours, with a total of 23 blood samples missing for 
the entire study population. 10 missing samples were due to the death of patients, which is 
understandable, however five samples were “not taken by mistake”, four were not taken 
because of “technical difficulties”, and one was not taken for an unknown reason5. These seem 
to be careless errors to make in a major phase III clinical trial, especially since the results and 
recommendations have the potential to effect profound change on clinical practice. Given the 
weight of this study, a more thorough explanation of the missing samples would have been 
appropriate. 
 Further discrepancies can be noted in the phase III idarucizumab trial. The median 
maximum percentage reversal for patients in both groups A and B was determined to be 100% 
based on dTT and ECT results, yet only 98% of group A and 93% of group B had normalized 
dTT results, and only 89% of group A and 88% of group B had normalized ECT results. The 
authors conclude that “idarucizumab rapidly and completely reversed the anticoagulant activity 
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of dabigatran in 88 to 98% of patients”, but they do not say at what time interval or how many 
patients were able to be evaluated for inclusion in this calculation. They also gloss over the data 
showing that, at 12 and 24 hours, 10-46% of patients had dTT and ECT results greater than the 
ULN. 
 There is great potential for financial bias among these three studies. Boehringer 
Ingelheim Pharma funded both the phase I and phase III idarucizumab trials, provided financial 
compensation to the study participants and many of its authors, and produces both dabigatran 
(Pradaxa) and idarucizumab (Praxbind). Financial gain could provide an explanation for the 
discrepancies in the representation (or lack of) results. The same could be true for the PCC trial, 
as the study was funded by Sanquin, the producers of Cofact. However, the study’s authors 
presented their data in a much more transparent and clear manner.  
         A final potential limitation is creation of a study-specific upper limit of normal (ULN) for 
the coagulation assays used in the phase I and phase III idarucizumab trials. It is unclear why 
the study authors did not use existing reference ranges for these assays. In phase I study with 
idarucizumab, coagulation assays of 16 participants from a different study arm were used to 
calculate the study-specific ULN, which could affect its validity. The phase III idarucizumab trial 
uses the same study-specific ULN as determined in the phase I trial, but the actual values of the 
ULN for dTT and ECT are not stated in the primary research article or the supplementary 
appendix, and again, the reasoning for not using an existing reference range is unclear. In 
contrast, the PCC trial used standard reference ranges for PT, aPTT, ETP, and ECT, removing 
any question of accuracy or applicability when examining the results of this trial. 
 Despite the limitations of these studies, each has noteworthy strengths. Although neither 
idarucizumab study discussed its limitations, the Cofact study highlighted its limitations and 
discussed areas in need of further research. For example, a single dose of 50 IU/kg was 
administered in attempting anticoagulant reversal, and it is not known whether repeated or 
higher doses could reverse anticoagulation with dabigatran. All three trials’ simple design is a 
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strength in itself. Both the PCC and idarucizumab phase I trials were randomized, double-blind 
placebo-controlled trials, which are the gold standard for demonstrating efficacy. The phase III 
idarucizumab trial has a prospective cohort study design, an unavoidable weakness, as it would 
be unethical to without potential treatment from patients presenting with major bleeding. Yet 
although healthy participants are a criterion for phase I trials studying the efficacy of a new drug, 
a healthy study population does not generally represent the target patient population. In the 
phase III idarucizumab study, the lack of a control group is countered by the use of a clinically 
relevant study population.  
 Another strength of the phase I and phase III idarucizumab trials were their use of 
several coagulation assays to determine which was most reliable as a measure of outcome. The 
studies also used mass spectrometry to assess the plasma concentrations of total and unbound 
dabigatran, which were used to correlate with and assess the most reliable coagulation assay 
for observing dabigatran reversal by idarucizumab. Finally, adverse events were reported, and 
in the phase III idarucizumab study, a contracted company (SGS Life Sciences Clinical 
Research Services) was employed to adjudicate any adverse events and to decide on their 
relationship, if any, to treatment with idarucizumab. 
 While the results are favorable, the limitations of these studies are significant, and, as 
this clinical question is an important and relevant one, further studies should recognize these 
weaknesses to further address these limitations to improve the research. 
 
Conclusion 
 
 Both Cofact and idarucizumab have demonstrated effective reversal of rivaroxaban and 
dabigatran, respectively. However, as of December 2015, Cofact has not been approved by the 
FDA for reversal of NOACs in the United States. Conversely, in October 2015, idarucizumab 
(Praxbind) was approved by the FDA for reversing anticoagulation with dabigatran. Current 
pricing of a single    5 g dose of idarucizumab is $3,5006. Because idarucizumab is currently 
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available for clinical use, dabigatran is a preferable alternative to rivaroxaban and the other 
factor Xa inhibitors for adults requiring oral anticoagulation, due to the existence of an effective 
reversal agent.. However, the decision about which oral anticoagulant to use remains at the 
discretion of the patient and clinician based on an assessment of patient-specific risks and 
benefits, and clinicians should continue to exercise caution in prescribing dabigatran etexilate, 
based on the limitations of the idarucizumab phase III trial. Idarucizumab did successfully 
reverse anticoagulation of dabigatran at up to 24 hours in most patients, but a subset of patients 
did not experience sustained or effective reversal with this drug. Clinical characteristics, 
particularly kidney function, comorbidities, and concurrent antithrombotic treatments such as 
Plavix or aspirin are not known for this subset of patients, which allow for ambiguous 
interpretation of the study data, as failure of reversal with idarucizumab could be due to patient 
characteristics or inefficacy of the drug. The authors and those conducting the phase III 
idarucizumab trial need to reevaluate their study protocols for blood sample collection and the 
presentation of relevant data. The distribution of patients, rather than quartiles, could be more 
useful in evaluating the clinical significance of the study results.  
 Additional study with idarucizumab is needed to determine if reversal outcomes could be 
improved by administering more than one dose of idarucizumab, as some patients had elevated 
dTT and ECT results one hour after receiving 5 g of idarucizumab. The reversal of rivaroxaban 
with Cofact is promising, however further, more current research must be conducted in a larger 
and different population, beyond phase I study. 
 A few weeks before submission of this review, an article was published in the New 
England Journal of Medicine detailing the results of an exciting clinical trial evaluating the 
efficacy of a new pharmaceutical, andexanet alfa, for the reversal of anticoagulation with factor 
Xa inhibitors. These studies, ANNEXA-A and ANNEXA-R, were randomized control trials 
examining reversal of anticoagulation with apixaban and rivaroxaban in 145 healthy volunteers 
ages 50 to 75 years. Both studies demonstrated safe, rapid, and effective reversal of apixaban 
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and rivaroxaban with andexanet alfa, and the authors proposed that andexanet alfa could be a 
potentially universal antidote for patients anticoagulated with direct and indirect factor Xa 
inhibitors. There are ongoing studies with andexanet alfa in patients with major bleeding as part 
of the ANNEXA-4 clinical trial (ClinicalTrials.gov Identifier: NCT02329327)7. This recent NEJM 
publication highlights again how important it is for clinicians who prescribe oral anticoagulants, 
particularly NOACs, to continually stay updated concerning new reversal agents for these drugs.  
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